Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Development Of Prototype Scanner Designed To Help Police Identify Criminals Carrying Guns And Knives
Scientists have developed a prototype scanner designed to help police identify criminals carrying guns and knives without putting themselves in the line of attack.
generic viagra online
Pharmasset Nominates PSI-938 As A New Nucleotide Analog Inhibitor Of Hepatitis C For Preclinical Development
Pharmasset, Inc. (Nasdaq: VRUS) announced the nomination of PSI-352938 ("PSI-938") as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is a proprietary nucleotide analog polymerase inhibitor of HCV that is being advanced into studies required for submission of an Investigational New Drug (IND) application with the FDA or equivalent foreign regulatory application.
News of the day
Closely Supervised Foster Care Linked With Reduced Pregnancy Rates For Delinquent Teens, Study Says
Teenage girls with a history of delinquency who were placed in individualized foster care programs were less likely than their peers to become pregnant, according to a study in the June issue of the Journal of Consulting and Clinical Psychology, HealthDay/Forbes reports. Teen girls in foster care have an elevated risk for pregnancy, according to HealthDay/Forbes. For example, an earlier survey of teens in three states found that nearly half of girls in the foster care system reported a pregnancy by age 19, according to David Kerr, an assistant professor of psychology at Oregon State University and lead author of the new study.For the study, researchers followed 166 girls ages 13 to 17 with court orders to receive treatment for criminal behavior in either specialized foster care or a group-care facility. The specialized programs, known as Multidimensional Treatment Foster Care, were created in the 1980s. Under the programs, foster parents who are trained in behavioral management provide one-on-one care to severely delinquent youths, and the parents receive consultation, support and crisis intervention services from program supervisors. One of the most important aspects of the program is that, unlike group care, the teens are isolated from other troubled youths. There are 51 such programs in the U.S.After two years, 26% of the girls in MTFC became pregnant, compared with almost 47% of those in group care, according to the study. The MTFC group also showed lower levels of criminal activity and arrests, and increased school engagement. Kerr said, "One of the most interesting aspects of this research is that the MTFC program was created to reduce crime, not pregnancy." He added, "It specifically targeted changing the girl"s environment: her home, her peers and her school experience. The focus was on giving her lots of supervision, support for responsible behavior, and consistent, non-harsh consequences for negative behavior" (HealthDay/Forbes, 6/17).
Mental Health

Transcend Medical Raises $35 Million Series B Round Towards Development Of Novel Glaucoma Treatment

Transcend Medical, Inc., an ophthalmic device company dedicated to delivering breakthrough advances in the treatment of glaucoma, announced today that it has closed a $35 million Series B round and is continuing the rapid development of its Transcend CyPass(TM) System, a novel proprietary system for the minimally-invasive treatment of glaucoma. Lead investor HLM Venture Partners, along with other new investors Canaan Partners, Technology Partners and Latterell Venture Partners made significant contributions to this round of financing, which was also strongly supported by current investors Morgenthaler Ventures and Split Rock Partners. "Completing this round is a testament to the progress of our technology and a strong validation of its potential to impact the future of glaucoma treatment," said Brian Walsh, President and Chief Executive Officer of Transcend Medical. "We are now well-capitalized to accomplish all initial clinical and commercial milestones for the company." The Transcend CyPass System is being developed to both replace current glaucoma therapies, which either lack effectiveness or are very invasive, and to expand treatment to a much larger patient population. Transcend Medical is focused on a less invasive procedure using a novel, proprietary system that reduces intraocular pressure (IOP). "There is a significant need to improve how we treat glaucoma," commented Eugene de Juan, Jr., M.D., Jean Kelly Stock Distinguished Professor of Ophthalmology at UCSF and Founder of Transcend Medical. "Today"s treatment options for glaucoma are highly limited and only feasible in a limited portion of those affected by the disease worldwide." "We are encouraged by the CyPass System"s minimally invasive delivery which is of significant benefit to patients, provides important ease of use features for physicians, and could result in earlier intervention in the glaucoma disease process," added Ike Ahmed, M.D., Assistant Professor, University of Toronto who is a world renowned glaucoma specialist and a clinical investigator of the CyPass System. "The CyPass System has shown promising initial results in a challenging population, with a very straight-forward procedure. We have been quite impressed with our experience to date in this growing patient group." About Transcend Medical, Inc. Transcend Medical is focused on the research and development of medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. It is estimated that nearly four million people in the U.S. and 70 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the U.S. and to over 80 million worldwide by the year 2013. Based in Menlo Park, Calif., Transcend Medical was the first company to be spun out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009